Compare CANF & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANF | SMTI |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 208.8M |
| IPO Year | 2011 | 2008 |
| Metric | CANF | SMTI |
|---|---|---|
| Price | $3.24 | $21.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $50.00 | $34.00 |
| AVG Volume (30 Days) | ★ 77.0K | 39.6K |
| Earning Date | 03-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $15,586,976.00 |
| Revenue This Year | $2,715,455.50 | $17.31 |
| Revenue Next Year | $101.06 | $12.48 |
| P/E Ratio | ★ N/A | $459.60 |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $0.17 | $16.05 |
| 52 Week High | $10.40 | $35.70 |
| Indicator | CANF | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 46.55 | 54.27 |
| Support Level | $3.20 | $18.20 |
| Resistance Level | $3.60 | $24.17 |
| Average True Range (ATR) | 0.18 | 1.43 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 17.31 | 39.34 |
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.